MaxCyte, Inc. Total Voting Rights
March 01 2024 - 12:57PM
RNS Regulatory News
RNS Number : 3496F
MaxCyte, Inc.
01 March 2024
MaxCyte,
Inc.
("MaxCyte" or the "Company")
Total Voting
Rights
ROCKVILLE, Maryland - 1 March
2024: MaxCyte Inc.,
(NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused
company providing enabling platform technologies to advance the
discovery, development and commercialization of next-generation
cell therapeutics and innovative bioprocessing
applications, announces that pursuant
to its block admission facility, since 31 January 2024 it has
issued 86,519 of
common stock, $0.01 par, of the Company ("Common Stock") in
satisfaction of the exercise of share options and/or vesting of
restricted stock units.
Total voting rights
As at 29 February 2024, the total
issued stock capital of the Company following the recent issue of
the new Common Stock is 104,096,750 shares of Common Stock.
Shareholders in the Company may use this figure as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the stock capital of the Company.
For further information, please
contact:
|
MaxCyte Contacts:
US IR
Adviser
Gilmartin Group
David Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure Gordon
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
|
UK IR
Adviser
ICR
Consilium
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
|
|
|
|
|
|
|
|
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx ™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on Twitter and LinkedIn.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
TVRQKDBPOBKDANK
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Sep 2023 to Sep 2024